Table 3.
Patients | Type | Number | Follow-up | End-point | Outcome | |
---|---|---|---|---|---|---|
Ilkova et al. [50] | Newly diagnosed T2DM | CSII for 2 weeks | 13 | 6 months | FPG <7.8 mmol/L or PPG <10.0 mmol/L | 69% |
Li et al. [51] | Newly diagnosed T2DM | CSII for 2 weeks | 138 | 2-year | FPG <7.0 mmol/L or PPG <10.0 mmol/L | 42% |
Weng et al. [52] | Newly diagnosed T2DM | CSII vs. MDI vs. OHA for 2 weeks | 124 vs. 113 vs. 94 | 1-year | FPG <6.1 mmol/L or PPG < 8.0 mmol/L | 51% vs. 45% vs. 27% |
Chen et al. [53] | Newly diagnosed T2DM | CSII for 2 weeks | 118 | 1-year | FPG <7.0 mmol/L or PPG <10.0 mmol/L | 55% |
Chon et al. [54] | Newly diagnosed T2DM | MDI vs. OHA for 12 weeks | 50 vs. 47 | 2-year | HbA1c <7% | 47% vs. 23% |
T2DM, type 2 diabetes mellitus; CSII, continuous subcutaneous insulin infusion; FPG, fasting plasma glucose; PPG, postprandial plasma glucose; MDI, multiple daily insulin injection; OHA, oral hypoglycemic agent; HbA1c, glycosylated hemoglobin.